Pierre-Andre Chavaillaz
Keine laufenden Positionen mehr
Profil
Pierre-Andre Chavaillaz joined Altor BioScience Corp.
in 2005, and currently serves as Director of Product Development.
Dr. Chavaillaz was appointed as a Member of the Sunol Molecular Corp.
in 1996 and worked with Baxter Healthcare and Dade International.
He obtained post-doctoral training at the University of Sherbrooke, Quebec, Canada, and at the University of Bern, Switzerland.
Dr. Chavaillaz received a Master's Degree in Organic Chemistry and Doctorate degree in Biochemistry from the University of Fribourg.
Ehemalige bekannte Positionen von Pierre-Andre Chavaillaz
| Unternehmen | Position | Ende |
|---|---|---|
| Dade International, Inc. | Corporate Officer/Principal | - |
Sunol Molecular Corp.
 Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Corporate Officer/Principal | - |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Corporate Officer/Principal | - |
Altor BioScience Corp.
 Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | Corporate Officer/Principal | - |
Ausbildung von Pierre-Andre Chavaillaz
| University of Fribourg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Altor BioScience Corp.
Altor BioScience Corp. Pharmaceuticals: MajorHealth Technology Altor BioScience Corp. operates as a biopharmaceutical company which develops therapeutic products for the treatment of cancer. Its product candidates include ALT-801, a T-cell receptor-targeted immunotherapeutic for cancer and ALT-836, a monoclonal antibody-based tissue factor antagonist treatment of patients with acute respiratory distress syndrome and acute lung injury. The company was founded by Hing C. Wong in 2002 and is headquartered in Miramar, FL. | Health Technology |
Sunol Molecular Corp.
Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Health Technology |
Baxter Healthcare Corp.
Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Health Technology |
| Dade International, Inc. | Health Technology |